| 5/14/2021 |
Health Care Stocks: These 7 Are Breaking Down; What You Need To Know | Investor's Business Daily |
investors.com |
... strength. But diving below is considered a sign of weakness.Health care stocks like Dexcom and Tandem now belong to that category. The list also includes genomics-centric companies like Illumina ( ILMN ), Invitae ( NVTA ), NeoGenomics ( NEO ) and 10x Genomics ( TXG ). It also includes generic drugs company Aclaris Therapeutics ( ACRS ).Health Care Stocks: Watching This Line Dexcom and Tandem stocks fell below their 50-day line on May 4 and May ... |
| 5/13/2021 |
NeoGenomics – Consensus Indicates Potential -11.3% Downside |
directorstalkinterviews.com |
... for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics has a strategic collaboration with Inivata Limited for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States. NeoGenomics was founded in 2001 and is headquartered in Fort Myers, Florida.Good news ... |
| 5/13/2021 |
State of New Jersey Common Pension Fund D Has $3.39 Million Stock Position in NeoGenomics, Inc. (NASDAQ:NEO) | Daily Political |
Daily Political |
State of New Jersey Common Pension Fund D reduced its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 5.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 70,193 shares of the medical research company’s stock after selling 3,892 shares during the quarter. State of New Jersey Common Pension Fund D owned about 0.06% of NeoGenomics ... |
| 5/13/2021 |
State of New Jersey Common Pension Fund D Lowers Position in NeoGenomics, Inc. (NASDAQ:NEO) - Ticker Report |
Ticker Report |
State of New Jersey Common Pension Fund D lessened its position in NeoGenomics, Inc. (NASDAQ:NEO) by 5.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 70,193 shares of the medical research company’s stock after selling 3,892 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in NeoGenomics were worth $3,385,000 ... |
| 5/13/2021 |
State of New Jersey Common Pension Fund D Has $3.39 Million Stock Position in NeoGenomics, Inc. (NASDAQ:NEO) - American Banking News |
American Banking News |
State of New Jersey Common Pension Fund D Has $3.39 Million Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)State of New Jersey Common Pension Fund D reduced its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 5.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 70,193 shares of the medical research company’s stock after selling ... |
| 5/13/2021 |
DekaBank Deutsche Girozentrale Purchases 24,300 Shares of NeoGenomics, Inc. (NASDAQ:NEO) |
Dakota Financial News |
DekaBank Deutsche Girozentrale increased its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 972.0% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 26,800 shares of the medical research company’s stock after buying an additional 24,300 shares during the period. DekaBank Deutsche Girozentrale’s holdings in NeoGenomics were worth $1,197,000 at the end of the most recent reporting period ... |
| 5/12/2021 |
NeoGenomics (NASDAQ:NEO) Issues FY 2021 Earnings Guidance - WKRB News |
wkrb13.com |
... of 0.25, a quick ratio of 6.22 and a current ratio of 6.54. The stock has a 50-day moving average price of $47.71 and a two-hundred day moving average price of $49.50. NeoGenomics has a 1 year low of $25.19 and a 1 year high of $61.57. The stock has a market cap of $4.51 billion, a price-to-earnings ratio of -1,286.24 and a beta of 0.79 ... |
| 5/12/2021 |
NeoGenomics (NASDAQ:NEO) Releases FY 2021 Earnings Guidance |
zolmax.com |
... The company issued revenue guidance of $490 million-$510 million, compared to the consensus revenue estimate of $498.21 million.Several research analysts have issued reports on the stock. Zacks Investment Research cut shares of NeoGenomics from a hold rating to a sell rating in a report on Wednesday, April 28th. Morgan Stanley raised their price target on shares of NeoGenomics from $46.00 to $64.00 and gave the company an overweight ... |
| 5/11/2021 |
The Ridgway Record |
ridgwayrecord.com |
FT. MYERS, FL / ACCESSSWIRE / May 10, 2021 / NeoGenomics , Inc. ( NASDAQ:NEO ), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Executive Chairman, Mark Mallon, Chief Executive Officer, and Kathryn McKenzie, Chief Financial Officer, will be presenting at the Bank of America 2021 Health Care Conference, on Wednesday, May 12, 2021 at 4:15pm ET.The presentation will be webcast live ... |
| 5/11/2021 |
NeoGenomics, Inc. (NASDAQ:NEO) Expected to Post Quarterly Sales of $118.14 Million | Daily Political |
Daily Political |
Equities research analysts forecast that NeoGenomics , Inc. (NASDAQ:NEO) will report $118.14 million in sales for the current fiscal quarter, according to Zacks Investment Research . Four analysts have issued estimates for NeoGenomics ’ earnings. The highest sales estimate is $121.79 million and the lowest is $113.50 million. NeoGenomics posted sales of $86.98 million during the same quarter last year, which suggests a positive year-over-year growth rate of 35.8 ... |
| 5/11/2021 |
Comerica Bank Raises Holdings in NeoGenomics, Inc. (NASDAQ:NEO) | Daily Political |
Daily Political |
Comerica Bank increased its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 1.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 117,742 shares of the medical research company’s stock after buying an additional 1,603 shares during the period. Comerica Bank’s holdings in NeoGenomics were worth $5,966,000 at the end of the most recent reporting period. Other large ... |
| 5/11/2021 |
NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Exane Derivatives - WKRB News |
wkrb13.com |
Exane Derivatives cut its stake in NeoGenomics , Inc. (NASDAQ:NEO) by 29.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,380 shares of the medical research company’s stock after selling 2,273 shares during the period. Exane Derivatives’ holdings in NeoGenomics were worth $259,000 at the end of the most recent reporting period.A ... |
| 5/11/2021 |
NeoGenomics – Consensus Indicates Potential -11.3% Downside |
directorstalkinterviews.com |
... for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics has a strategic collaboration with Inivata Limited for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States. NeoGenomics was founded in 2001 and is headquartered in Fort Myers, Florida.This article ... |
| 5/10/2021 |
NeoGenomics – Consensus Indicates Potential -11.3% Downside |
directorstalkinterviews.com |
... for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics has a strategic collaboration with Inivata Limited for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States. NeoGenomics was founded in 2001 and is headquartered in Fort Myers, Florida ... |
| 5/10/2021 |
Global In Situ Hybridization Market (2021 to 2025) - Featuring Abbott Laboratories, Agilent Technologies and PerkinElmer Among Others - ResearchAndMarkets.com |
Yahoo News |
The "Global In Situ Hybridization (ISH) Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.The publisher has been monitoring the in situ hybridization (ISH) market and it is poised to grow by $475.05 million during 2021-2025, progressing at a CAGR of about 7% during the forecast period. The report on in situ hybridization (ISH) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as ... |
| 5/10/2021 |
Global In Situ Hybridization Market (2021 to 2025) - Featuring Abbott Laboratories, Agilent Technologies and PerkinElmer Among Others - ResearchAndMarkets.com - Stocks News Feed |
stocksnewsfeed.com |
... driving the in situ hybridization (ISH) market growth during the next few years.Companies MentionedAbbott Laboratories Agilent Technologies Inc. Bio-Rad Laboratories Inc. Bio-Techne Corp. F . Hoffmann-La Roche Ltd. Merck KGaA NeoGenomics Laboratories Inc. PerkinElmer Inc. QIAGEN NV Thermo Fisher Scientific Inc. The report on in situ hybridization (ISH) market covers the following areas:In situ hybridization (ISH) market sizing In situ hybridization (ISH) market forecast In ... |
| 5/10/2021 |
Global In Situ Hybridization Market (2021 to 2025) - Featuring Abbott Laboratories, Agilent Technologies and PerkinElmer Among Others - ResearchAndMarkets.com | Business Wire |
Business Wire |
... driving the in situ hybridization (ISH) market growth during the next few years.Companies MentionedAbbott Laboratories Agilent Technologies Inc. Bio-Rad Laboratories Inc. Bio-Techne Corp. F. Hoffmann-La Roche Ltd. Merck KGaA NeoGenomics Laboratories Inc. PerkinElmer Inc. QIAGEN NV Thermo Fisher Scientific Inc. The report on in situ hybridization (ISH) market covers the following areas:In situ hybridization (ISH) market sizing In situ hybridization (ISH) market forecast In ... |
| 5/10/2021 |
The Ridgway Record |
ridgwayrecord.com |
... driving the in situ hybridization (ISH) market growth during the next few years.Companies MentionedAbbott Laboratories Agilent Technologies Inc. Bio-Rad Laboratories Inc. Bio-Techne Corp. F. Hoffmann-La Roche Ltd. Merck KGaA NeoGenomics Laboratories Inc. PerkinElmer Inc. QIAGEN NV Thermo Fisher Scientific Inc. The report on in situ hybridization (ISH) market covers the following areas:In situ hybridization (ISH) market sizing In situ hybridization (ISH) market forecast In ... |
| 5/10/2021 |
|
malvern-online.com |
... driving the in situ hybridization (ISH) market growth during the next few years.Companies MentionedAbbott Laboratories Agilent Technologies Inc. Bio-Rad Laboratories Inc. Bio-Techne Corp. F. Hoffmann-La Roche Ltd. Merck KGaA NeoGenomics Laboratories Inc. PerkinElmer Inc. QIAGEN NV Thermo Fisher Scientific Inc. The report on in situ hybridization (ISH) market covers the following areas:In situ hybridization (ISH) market sizing In situ hybridization (ISH) market forecast In ... |
| 5/10/2021 |
NeoGenomics, Inc. (NASDAQ:NEO) Position Lessened by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp - American Banking News |
American Banking News |
NeoGenomics, Inc. (NASDAQ:NEO) Position Lessened by BRITISH COLUMBIA INVESTMENT MANAGEMENT CorpBRITISH COLUMBIA INVESTMENT MANAGEMENT Corp decreased its stake in NeoGenomics , Inc. (NASDAQ:NEO) by 38.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 156,000 shares of the medical research company’s stock after selling 97,900 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT ... |